Latest DDSC news
Teva and Samsung Bioepis announce agreement to commercialise two FDA-approved biosimilars in the US
Teva Pharmaceutical and Samsung Bioepis have signed a license and commercialisation agreement for two FDA-approved immunology biosimilars: infliximab-abda, a...
Bayer’s asundexian first FXIa inhibitor approved by US Food and Drug Administration for secondary stroke risk reduction
The US Food and Drug Administration has granted marketing authorisation for Bayer's asundexian, 50 mg tablets, under the brand...
PacBio and Verily Health announce multi-year strategic collaboration to scale long-read genomics for biomedical AI
PacBio, a developer of advanced sequencing technologies, and Verily Health, a healthcare data intelligence company, have announced a multi-year strategic...
ScionxBio announces collaboration to develop long-acting xRNA therapeutics
ScionxBio has entered into a worldwide strategic collaboration and licensing agreement with Sanofi to develop and commercialise extended exposure...
Armenia grants first marketing authorisations for Agenus’ BOT+BAL in previously treated MSS metastatic colorectal cancer
The Ministry of Health of the Republic of Armenia has granted marketing authorisations for Agenus’ Botvymo (botensilimab, BOT) and Evamplix (balstilimab,...
Sterling expands ADC manufacturing capacity and capabilities
Contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has announced completion of an additional, large-scale GMP manufacturing suite...
Merck to outsource CDMO business to specialist Lonza
Merck, a leading science and technology company, has signed a definitive agreement to divest its contract development and manufacturing...
Rznomics granted orphan medicinal product designation for RZ-001 for the treatment of glioma by the European Commission
Rznomics Inc, a biopharmaceutical company specialising in the development of RNA-based gene therapies, announced that the European Commission (EC)...
ESTEVE CDMO strengthens global manufacturing footprint with major investment and new site in China
Esteve CDMO, Esteve's Healthcare contract development and manufacturing organisation, is strengthening its global manufacturing footprint through the relocation, expansion...
Samsung Bioepis and Teva expand strategic partnership to advance up to six potential biosimilar candidates
Samsung Bioepis and Teva Pharmaceutical have entered into a global licence, development and commercialisation agreement for up to six...
Bespak expands next-generation nasal offering with launch of NasaDose ultra soft unit dose spray
Bespak, a specialist inhalation contract development and manufacturing organisation (CDMO) focused exclusively on inhaled and nasal drug delivery, will...
Dr Oregonin completes US FDA registration for Oltis Dental-X, unveiling oral-care innovation rooted in trans-Pacific alder research
Dr Oregonin Inc has completed US Food and Drug Administration (FDA) registration for OLTIS DENTAL-X, paving the way for...
- Advertisement -
- Advertisement -
- Advertisement -
Popular
© 2026 Pharma Press Global.


